New stem cell processing method aims to prevent transplant complications

NCT ID NCT06047886

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated May 23, 2026 · Updated 6 times

Summary

This study tests a new automated method to select specific stem cells (CD34+) for transplant in people with blood cancers like leukemia or lymphoma. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. About 50 participants will receive this processed stem cell boost or transplant. The study is in early stages (Phase 1) and focuses on safety and feasibility.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294-3300, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALL AML CML LYMPHOID MALIGNANCIES MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES PRIMARY MYELOFIBROSIS